Soliris Reduces Risk of Relapse, Kidney Transplant Loss, Study Finds
Soliris (eculizumab), given as a treatment or as a preventive measure, reduces disease relapse and kidney transplant loss in people with atypical hemolytic uremic syndrome (aHUS), according to a Brazilian retrospective study. Researchers emphasized the need, in low- to medium-income countries, to provide greater access to Soliris and similar…